Explain pharmacovigilance and provide an example of how it affects prescribing decisions.

• A. Monitoring adverse drug events; example: post-marketing reports lead to label warnings or withdrawal of a drug.
• B. Pharmacovigilance only concerns marketing campaigns.
• C. Pharmacovigilance is the same as quality assurance testing.
• D. It is only relevant to new drugs and has no impact on established therapies.

Answer: (A)

Pharmacovigilance is the ongoing monitoring of a drug’s safety after it reaches the market, collecting and evaluating adverse events and safety signals to protect patients. It relies on reports from clinicians and patients, post-marketing studies, and signal detection to determine if risks seen in real-world use match or exceed what was known from trials. This information can trigger regulatory actions such as updating labeling with new warnings, adjusting dosing or contraindications, restricting use in certain populations, or withdrawing the drug from the market. When prescribing, you factor in these evolving safety data and may implement closer monitoring or choose alternative therapies if risks appear significant. For example, post-marketing findings might reveal a rare but serious cardiac risk, leading to a boxed warning, new monitoring requirements, or even removal of the drug, which directly shapes how you decide to use it with patients.